Vous préférez recevoir notre infolettre en français?
Modifiez vos préférences ici.

Renewed Government Support for CATALIS Quebec

The pandemic has definitively demonstrated the ultimate importance of fundamental and clinical research to prevent diseases and improve the health of patients. On the eve of INTERNATIONAL CLINICAL RESEARCH DAY, CATALIS is delighted to once again benefit from the support of the Quebec government under the new version of The Quebec Life Sciences Strategy 2022-2025, which was unveiled last week by the Minister of Economy and Innovation, Pierre Fitzgibbon.

This renewed support will allow CATALIS, in collaboration with its network of partners, to pursue its government's mandate of optimizing the clinical research environment in Quebec, in order to provide easy access to clinical trials in the province for all seeking patients.

Two New Projects Successfully Authorized Within

7 Weeks Thanks to CATALIS’ FAST TRACK  Service

While the first-ever FAST TRACK evaluation service pilot project was successfully completed last December, CATALIS is proud to announce that two more clinical trials have now been approved in record time.

The second FAST TRACK evaluation service coordinated a Phase I oncology study on advanced solid tumours by the Boehringer Ingelheim Canada (BI Canada Ltd) pharmaceutical company. This study was also authorized in a record-setting time of seven weeks by the Centre de recherche du Centre hospitalier de l’Université de Montréal (CR-CHUM) research centre. As a result, the CR-CHUM has positioned itself as the fastest site in the world to have been activated.

“The FAST TRACK process in Quebec has demonstrated a strong commitment to revolutionize the clinical trial start up process with the aim to accelerate clinical development and expedite access to innovative medicines for patients. Boehringer Ingelheim Canada Ltd. is excited to see the success of the Quebec-based FAST TRACK service, which is an important collaboration endeavor that places the province in a favorable position globally to attract clinical research, and especially early clinical research.”

- Gabriel Kim, Vice President, medical and regulatory affairs, BI Canada Ltd.

During this same period, Novartis Canada’s Phase III NEOS study, which seeks to assess the efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis, was authorized within seven weeks by The Neuro (Montreal Neurological Institute-Hospital).

In its pilot phase, CATALIS’ FAST TRACK evaluation service has made it possible to reduce a clinical trial’s approval time frame by nearly 75% for a third consecutive time.

You can follow the progress of the FAST TRACK pilot project on our website.

BAYER Joins the CATALIS Network

CATALIS Quebec is very proud to expand its network of partners with the addition of Bayer to its ranks. Bayer is the 10th pharmaceutical company to join the CATALIS network, an expert network which already includes some 50 organizations. Bayer joins other CATALIS pharmaceutical members Abbvie, Boehriger Ingelheim, GSK, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda.

"Bayer is dedicated to advancing health and nutrition worldwide and is committed to delivering “Science for a better life” through a portfolio of innovative treatments. We are very excited to forge a partnership with CATALIS as it will facilitate our conduct of clinical trials in Quebec and help us improve patient outcomes by expediting the development of new and innovative therapies. We look forward to working with CATALIS and their network of Quebec partners for our upcoming clinical trials."

Dr. Shurjeel Choudhri, Senior Vice President and Head of Medical and Scientific Affairs at Bayer

Launch of New Shared Clinical Research Tools

CATALIS and its network of public and private partners have facilitated the implementation of new shared tools designed to optimize the launching and conducting of clinical trials in Quebec; more specifically, CATALIS has coordinated the revision of tow (2) new documents serving to optimize the contract negotiation process with private industry, as well as a memo which serves to clarify the use of form FDA 1572 in Quebec health institutions.

Job Offer



View Job Offer

CATALIS Quebec is a non-profit partnership dedicated to the advancement and operational excellence of clinical research in Quebec.

Since 2017, CATALIS Quebec has been carrying out a large-scale government mandate to optimize Quebec’s clinical research environment. The CATALIS network's efforts are focused on providing more Quebec patients with access to tomorrow’s therapies.

Follow us on Twitter and LinkedIn to learn why Québec is a world leader in clinical trials.